Qtron Investments LLC Has $541,000 Holdings in United Therapeutics Corporation $UTHR

Key Points

• Qtron Investments LLC increased its stake in United Therapeutics Corporation by 131.7% in the first quarter, holding shares now worth $541,000 after purchasing additional shares.
• Insider transactions have been notable, with Director Richard Giltner and CFO James Edgemond selling thousands of shares, reducing their ownership significantly by 13.54% and 59.65%, respectively.
• Analysts have mixed views on the stock, with UBS raising its price target to $415.00 while others provided lower target prices, resulting in a consensus target price of $382.00.

Qtron Investments LLC boosted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 131.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,754 shares of the biotechnology company's stock after purchasing an additional 997 shares during the quarter. Qtron Investments LLC's holdings in United Therapeutics were worth $541,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $18,257,000. Mariner LLC lifted its stake in shares of United Therapeutics by 7.7% in the fourth quarter. Mariner LLC now owns 4,200 shares of the biotechnology company's stock valued at $1,482,000 after buying an additional 299 shares during the period. Jump Financial LLC acquired a new position in United Therapeutics in the 4th quarter valued at approximately $369,000. NewEdge Advisors LLC raised its holdings in United Therapeutics by 124.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,027 shares of the biotechnology company's stock valued at $1,068,000 after acquiring an additional 1,679 shares in the last quarter. Finally, Commerce Bank raised its holdings in United Therapeutics by 7.6% in the 4th quarter. Commerce Bank now owns 1,408 shares of the biotechnology company's stock valued at $497,000 after acquiring an additional 100 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on UTHR shares. HC Wainwright set a $400.00 price target on United Therapeutics and gave the company a "buy" rating in a report on Thursday, July 31st. Cantor Fitzgerald reissued an "overweight" rating on shares of United Therapeutics in a report on Thursday, August 14th. Morgan Stanley dropped their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Bank of America decreased their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. Finally, JPMorgan Chase & Co. dropped their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $382.00.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 645 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 92,681 shares of company stock worth $28,014,609. 10.30% of the stock is currently owned by insiders.

United Therapeutics Stock Performance

NASDAQ:UTHR traded up $1.57 on Friday, hitting $312.23. 576,473 shares of the stock were exchanged, compared to its average volume of 525,026. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The stock has a market capitalization of $14.08 billion, a price-to-earnings ratio of 12.19, a P/E/G ratio of 4.64 and a beta of 0.57. The company's 50-day moving average price is $296.44 and its 200 day moving average price is $307.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period last year, the firm earned $5.85 earnings per share. The company's quarterly revenue was up 11.7% on a year-over-year basis. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.